1. Magyari M, Koechlin A, Duclos A, Kopp TI, Allaoui EM, Polazzi S, Seeldrayers P, Autier P. Long-Term Safety of Teriflunomide in Multiple Sclerosis Patients: Results of Prospective Comparative Studies in Three European Countries. Pharmacoepidemiol Drug Saf. 2024 Jul;33(7):e5866.
2. Mahler MR, Magyari M, Pontieri L, Elberling F, Holm RP, Weglewski A, Poulsen MB, Storr LK, Bekyarov PA, Illes Z, Kant M, Sejbaek T, Stilund ML, Rasmussen PV, Brask M, Urbonaviciute I, Sellebjerg F. Prognostic factors for disease activity in newly diagnosed teriflunomide-treated patients with multiple sclerosis: a nationwide Danish study. J Neurol Neurosurg Psychiatry. 2024 Apr 3:jnnp-2023-333265. doi: 10.1136/jnnp-2023-333265. Epub ahead of print. PMID: 38569873.
3. Papp V, Magyari M, Möller S, Sellebjerg F, Battistini JL, Svendsen KB, Søndergaard HB, Nilsson AC, Illes Z. Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort. Neurology. 2024 Mar 12;102(5):e209147.
4. Framke E, Jennum PJ, Thygesen LC, Magyari M. Sleep disorders and sleep disturbances in persons with multiple sclerosis: A population-based matched case-control study in Denmark. Neuroepidemiology. 2024 Mar 21. doi: 10.1159/000538307. Epub ahead of print. PMID: 38513627.
5. Framke E, Thygesen LC, Malmborg M, Schou M, Sellebjerg F, Magyari M. Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: A nationwide cohort study of 2095 patients in Denmark. Mult Scler. 2024 Feb;30(2):184-191.
6. Koch-Henriksen NI, Thygesen LC, Sørensen PS, Magyari M. Using instrumental variables to correct for bias in real-world cohort studies of the effects of disease-modifying treatment in MS. Mult Scler. 2024 Jan;30(1):113-120.
7. Holm RP, Wandall-Holm MF, Sellebjerg F, Magyari M. Comorbidity in the aging population with multiple sclerosis: a Danish nationwide study. Front Neurol. 2023 Nov 24;14:1297709.
8. Butzkueven H, Hillert J, Soilu-Hänninen M, Ziemssen T, Kuhle J, Wergeland S, Magyari M, Berger JR, Moore N, Aydemir A, Bezemer I, Sabidó M. The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis. Curr Med Res Opin. 2023 Oct;39(10):1367-1374.
9. Kontaxis S, Laporta E, Garcia E, Martinis M, Leocani L, Roselli L, Buron MD, Guerrero AI, Zabala A, Cummins N, Vairavan S, Hotopf M, Dobson RJB, Narayan VA, La Porta ML, Costa GD, Magyari M, Sørensen PS, Nos C, Bailon R, Comi G, On Behalf Of The Radar-Cns Consortium. Automatic Assessment of the 2-Minute Walk Distance for Remote Monitoring of People with Multiple Sclerosis. Sensors (Basel). 2023 Jun 29;23(13):6017.
10. Wandall-Holm MF, Holm RP, Pontieri L, Sellebjerg F, Magyari M. Socioeconomic status of the elderly MS population compared to the general population: a nationwide Danish matched cross-sectional study. Front Neurol. 2023 Jun 13;14:1214897.